“A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes” (2025) Reumatismo [Preprint]. doi:10.4081/reumatismo.2025.1748.